<DOC>
	<DOCNO>NCT01229098</DOCNO>
	<brief_summary>The purpose study evaluate effect daily use LEO 80185 gel hypothalamic-pituitary-adrenal ( HPA ) axis calcium metabolism subject extensive psoriasis vulgaris .</brief_summary>
	<brief_title>Effect LEO 80185 Gel HPA Axis Calcium Metabolism Subjects With Extensive Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed date informed consent obtain follow receipt verbal write information study prior trial related activity ( include washout period ) . 2 . Age 18 year . 3 . Either sex . 4 . Any race ethnicity . 5 . Attending hospital outsubject clinic private practice dermatologist treatment psoriasis vulgaris . 6 . Clinical diagnosis psoriasis vulgaris involve non scalp region body ( trunk and/or limb ) without involvement scalp . 7 . At SV2 Day 0 ( Visit 1 ) clinical diagnosis psoriasis vulgaris : amenable topical treatment maximum 100 g study medication per week , extent 15 30 % body surface area ( BSA ) exclude psoriasis face , genitals skin fold . disease severity trunk and/or limb grade least moderate accord investigator 's global assessment ( IGA ) 8 . Subjects normal HPA axis function SV2 include serum cortisol concentration 5 mcg/dL ACTH challenge test 18 mcg/dL 30 minute ACTH challenge test . 9 . Albumincorrected serum calcium , upper reference limit SV2 . 10 . Females childbearing potential must negative urine pregnancy test result baseline Visit SV2 must agree use highly effective method contraception study . Highly effective method define one result low failure rate ( le 1 % per year ) progestinonly formulation ( implant , injectables ) , intrauterine device , vasectomise partner . Subjects must use contraceptive method continuously least 1 month prior pregnancy test must continue use contraceptive method least 1 week last application study medication ( study visit FU2 applicable ) . A female defined childbearing potential postmenopausal ( 12 month menses without alternative medical cause ) , surgically sterile ( tubal ligation/section , hysterectomy bilateral ovariectomy ) . 11 . Able communicate investigator understand comply requirement study . 12 . A history serious allergy , allergic asthma serious allergic skin rash 13 . Known suspected hypersensitivity medication ( include ACTH/cosyntropin/tetracosactide ) component LEO 80185 gel CORTROSYN . 14 . Systemic treatment corticosteroid ( include inhale nasal steroid ) within 12 week prior SV2 study . 15 . Systemic treatment biological therapy ( market market ) , possible effect psoriasis vulgaris within follow time period prior Day 0 ( Visit 1 ) study : etanercept within 4 week prior Visit 1 adalimumab , alefacept , infliximab within 2 month prior Visit 1 ustekinumab , briakinumab within 4 month prior Visit 1 experimental product within 4 weeks/5 halflives ( whichever longer ) prior Visit 1 16 . Systemic treatment therapy biologicals , possible effect psoriasis vulgaris ( e.g. , retinoids , methotrexate , immunosuppressant ) within 4 week prior Visit 1 ( Day 0 ) study . 17 . PUVA Grenz ray therapy within 4 week prior Visit 1 ( Day 0 ) study 18 . UVB therapy within 2 week prior Visit 1 ( Day 0 ) study . 19 . Topical treatment corticosteroid vitamin D analogue ( calcipotriol , calcitriol tacalcitol ) body location within 2 week prior SV2 study . 20 . Any topical treatment psoriasis vulgaris scalp trunk and/or limb ( except emollient nonsteroid medicate shampoo ) within 2 week prior Visit 1 ( Day 0 ) study . 21 . Oral calcium supplement , vitamin D supplement , antacid , thiazide and/or loop diuretic , antiepileptic , diphosphonates calcitonin within 4 week prior SV2 study . Note : Stable dos oral vitamin D supplementation â‰¤400 IU/day permit provide dose adjustment study period . 22 . Planned initiation , change , concomitant medication could affect psoriasis vulgaris ( e.g. , betablockers , antimalarial , lithium , ACE inhibitor ) study . 23 . Planned excessive exposure treat area either natural artificial sunlight ( e.g . sunlamp etc . ) study may affect psoriasis vulgaris . 24 . Oestrogen therapy ( include contraceptive ) medication know affect cortisol level HPA axis integrity within 4 week prior SV2 study . 25 . Cytochrome P450 3A4 ( CYP 3A4 ) inducer ( e.g. , barbiturate , phenytoin , rifampicin ) within 4 week prior SV2 study . 26 . Systemic topical cytochrome P450 3A4 ( CYP 3A4 ) inhibitor ( e.g. , ketoconazole , itraconazole , metronidazole ) within 4 week prior SV2 study . Topical ketoconazole within 2 week prior SV2 . 27 . Hypoglycaemic sulfonamide within 4 week prior SV2 study . 28 . Antidepressant medication within 4 week prior SV2 study . 29 . Not follow nocturnal sleep pattern ( e.g . night shift worker exclude ) . 30 . Known suspected endocrine disorder may affect result ACTH challenge test . 31 . Clinical sign symptoms Cushing 's disease Addison 's disease . 32 . Known suspected diabetes mellitus . 33 . Known suspected cardiac disorder associate abnormal QT interval rhythm disturbance include clinically significant bradycardia tachycardia . 34 . Known suspect severe renal insufficiency severe hepatic disorder . 35 . Known suspected disorder calcium metabolism associate hypercalcaemia . 36 . Any clinically significant abnormality follow review screen laboratory test ( blood spot urine sample ) , physical examination blood pressure/heart rate measurement perform SV2 . 37 . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . 38 . Any following condition present study treatment area : viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , acne rosacea , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer wound . 39 . Other inflammatory skin disease may confound evaluation psoriasis vulgaris ( e.g . seborrhoeic dermatitis , contact dermatitis cutaneous mycosis ) . 40 . Current participation interventional clinical trial . 41 . Previously enrol trial ( exception subject exclude due hypocalcaemia prior implementation Consolidated Clinical Study Protocol 2 ) . 42 . Received nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week 5 halflives ( whichever longer ) prior SV1 . 43 . Known suspect able comply trial protocol ( e.g. , alcoholism , drug dependency psychotic state ) . 44 . Females pregnant , positive urine pregnancy test baseline Visit SV2 , breastfeed . Females childbearing potential wishing become pregnant study use adequate method contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>